Platinum-based Chemotherapy
Surgery + Chemotherapy + IMRT for Mesothelioma
Recruiting1 awardPhase 2
Tampa, Florida
This trial is testing a new, safer radiation therapy for people with a certain type of lung cancer. The old radiation therapy had lots of side effects, but the new one specifically targets the cancer and reduces the risk of damaging healthy tissue.
Monoclonal Antibodies
NGM707 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Chemotherapy
VT3989 for Mesothelioma
Recruiting1 awardPhase 1
Houston, Texas
This trial tests a new drug, VT3989, for safety and effectiveness in patients with certain types of cancer that don't respond to other treatments. Researchers aim to find the best dose and see if the drug can help control the cancer.
Popular Filters
Trials for NSCLC Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
Recruiting1 awardPhase 1 & 2
Basking Ridge, New Jersey
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
Trials for Adenocarcinoma Patients
Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
Recruiting1 awardPhase 1 & 2
Basking Ridge, New Jersey
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
Immunotherapy
HFB200301 + Tislelizumab for Advanced Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests a new drug, HFB200301, alone and with another drug, tislelizumab, in adults with advanced cancers. Researchers will start with a low dose and gradually increase it to find the most suitable amount. They will then test this amount in more patients to see how well it works against different cancers.
Monoclonal Antibodies
NGM831 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called NGM831 alone or with other drugs in patients with advanced or spreading solid tumors. The goal is to see if these treatments can help stop the cancer or help the immune system fight it better. One of the drugs being tested has been widely studied and used in various cancers, showing significant improvements in survival rates and being effective in combination with other treatments.
Trials for Metastatic Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
Recruiting1 awardPhase 1 & 2
Basking Ridge, New Jersey
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
Immunotherapy
HFB200301 + Tislelizumab for Advanced Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests a new drug, HFB200301, alone and with another drug, tislelizumab, in adults with advanced cancers. Researchers will start with a low dose and gradually increase it to find the most suitable amount. They will then test this amount in more patients to see how well it works against different cancers.
Trials With No Placebo
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.